Another company which i believe will be on rally when it will start selling cancer vaccines in USA.
''Scancell Holdings plc is a biopharmaceutical company focussed on the cancer therapeutics market. It is developing a pipeline of deoxyribonucleic acid (DNA) vacancies for the treatment of cancer based on its ImmunoBody platform. The Company is principally engaged in the business of discovery and development of novel monoclonal antibodies and vaccines for the treatment of cancer. It is used for the treatment of melanoma. SCIB1 is a plasmid DNA which encodes a human antibody molecule engineered to express a melanoma antigen called Tyrosinase-Related Protein 2 (TRP2) plus two helper T cell epitopes. The Immunobody vaccines are used in the treatment of colorectal cancer. It may also be utilised in the treatment of infectious diseases. During the fiscal year ended April 30, 2010 (fiscal 2010), the Company owned 100% interest in its subsidiary, Scancell Limited.'' - Information provided by Google Finance
Therapeutic cancer vaccines specialist Scancell Holdings has unveiled the development of a new platform technology (Moditope) that stimulates the production of killer CD4 T cells with powerful anti-tumour activity. The directors believe that this new discovery could have a profound effect on the way that cancer vaccines are developed. CD4 responses to cancer associated antigens have been notoriously difficult to generate whether presented as peptides, proteins or DNA.CD4 cells are vital for effective anti-tumour immunity. Scancell has identified and patented a series of modified epitopes that overcome this limitation. Scancell's Moditope technology produces killer CD4 T cells that destroy tumours without toxicity.
Scancell Holdings joint chief executive and professor of cancer immunotherapy at Nottingham University, Professor Lindy Durrant, said: "Not only do these unique epitopes stimulate a CD4 killer T cell response, we have also shown in tests that cancer patients can produce an immune response to these epitopes.
Take a look at the 3 month chart:
It could be very good instrument for the term long investment,
Komentarų nėra:
Rašyti komentarą